Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer

Jianfa Li¹,²†, Chengle Zhuang¹,²,³†, Yuchen Liu¹†, Mingwei Chen¹,⁴†, Yincong Chen², Zhicong Chen¹,², Anbang He¹,⁴, Junhao Lin¹,², Yonghao Zhan¹,², Li Liu¹,², Wen Xu¹, Guoping Zhao⁵, Yinglu Guo⁶, Hanwei Wu¹, Zhiming Cai¹,²,⁴,⁵*, and Weiren Huang¹,²,⁴,⁶*

Abstract

Background: Long non-coding RNAs (lncRNAs) have been proved to act as key molecules in cancer development and progression. Dysregulation of lncRNAs is discovered in various tumor tissues and cancer cells where they can serve as oncogenes or tumor suppressors. Long non-coding RNA HOXD-AS (HOXD cluster antisense RNA 1) has recently been identified to be involved in the development of several cancers including neuroblastoma, adenocarcinomas and breast cancer. However, the role of HOXD-AS1 in bladder cancer remains unknown.

Methods: The synthetic tetracycline-controllable shRNA was used to modulate the level of HOXD-AS1 by adding different concentrations of doxycycline (dox). RT-qPCR was used to detect the expression level of HOXD-AS1. Cell proliferation was determined by CCK-8 assay and EdU incorporation experiment when HOXD-AS1 was knocked down. We used wound-healing assay for detecting the effect of HOXD-AS1 on cell migration. Eventually, cell apoptosis was determined by caspase 3 ELISA assay and flow cytometry assay.

Results: In this study, we found that the expression level of HOXD-AS1 was significantly increased in bladder cancer tissues and cells. Furthermore, high expression of HOXD-AS1 was significantly related to tumor size, histological grade and TNM stage. In vitro assays confirmed that knockdown of HOXD-AS1 suppressed cell proliferation/migration and increased the rate of apoptotic cell in bladder cancer cells. At last, we used the important element of synthetic biology, tetracycline(tet)-controllable switch, to construct tet-controllable shRNA vectors which can modulate the expression of HOXD-AS1 in a dosage-dependent manner.

Conclusions: Our research suggested that high expression of HOXD-AS1 may be involved in the bladder cancer carcinogenesis through inhibiting the phenotypes and activating endogenous cancer-related molecular pathways. Therefore, HOXD-AS1 may act as an oncogene and provide a potential attractive therapeutic target for bladder cancer. In addition, the synthetic tetracycline-controllable shRNA may provide a novel method for cancer research in vitro assays.

Keywords: Bladder cancer, lncRNA, HOXD-AS1, Synthetic biology, Tetracycline-controllable shRNA
Background
Bladder cancer is a fatal disease with high morbidity and mortality. It is estimated that 683,310 cases have been diagnosed in the United States each year. It has become the fourth most common tumor among men with morbidity almost 4 times than that among women [1]. Approximately 70 % of patients present non-muscle invasive bladder cancer (NMIBC) and patients with muscle-invasive bladder cancer (MIBC) account for the rest [2, 3]. Transurethral resection of bladder tumor (TURBT) and intravesical chemotherapy usually have been chosen to treat NMIBC, while radical cystectomy is used for high-grade muscle-invasive bladder cancer (MIBC). However, the recurrence rate for NMIBC ranges from 50 to 70 % and 50 % of MIBC patients died within 5 years despite active treatment [4–7].

Long non-coding RNAs are widely defined as transcripts longer than 200 nucleotides without open reading frames [8, 9]. Although IncRNAs could not be translated into proteins, they function as oncogenes or tumor suppressors, and exert important roles in the progression of malignant tumors [10]. HOXD-AS1 contains eight exons and its transcript is a novel IncRNA. It is transcribed from the HOXD cluster on human chromosome 2q31.2 in an antisense manner. HOXD-AS1 is up-regulated in neuroblastoma, adenocarcinomas and breast cancer. Moreover, it is closely associated with the progression and prognosis of these cancers [11–14]. HOXD is the member of HOX clusters of genes which involves in regulating embryogenesis and organogenesis. Dysregulation of HOX genes have been found in various cancers. They act as vital regulators in the processes of methylation and histone modification [15, 16]. However, there is no report about the role of HOXD-AS1 in bladder cancer.

Synthetic biology combines biological components and devices from different organisms to design and engineer artificial biological networks, pathways and systems that have novel functions and biomedical applications. Conveniently, these components can be created or obtained from different organisms [17–20]. Utilizing medical synthetic biology to fight against cancer has become a hot topic in recent years. Base on the principle and technology of synthetic biology, we used a standard method to synthesize tetracycline-controllable vectors which could modulate the expression of target gene in a dosage-dependent manner. This design provides a manageable research device to treat bladder cancer.

Here, we reveal the role of HOXD-AS1 in bladder cancer. Our data suggests that HOXD-AS1 may serve as an oncogene in the progression of bladder cancer, and a potential target for the bladder cancer treatments. Furthermore, the tetracycline-controllable shRNA can control the expression level of HOXD-AS1 in a dose-dependent manner and inhibit the development of bladder cancer cells, which may open up a novel way for treating bladder cancer.

Methods

Patients and tissue specimens
A total of 50 bladder cancer patients who underwent partial or radical cystectomy were included in this study. All specimens were stored in liquid nitrogen immediately after resection. The diagnosis was based on postoperative pathological analysis. The understanding of this study and written informed consent was received from each patient. The Institutional Review Board of Shenzhen Second People’s Hospital has approved this study.

Cell culture
The human bladder cancer cells (5637 and T24) and the human normal bladder epithelial cells (SV-HUC-1) were obtained from the Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The 5637 cells were grown in RPMI-1640 Medium (Gibco), supplemented with 10 % fetal bovine serum (Gibco) at 37 °C in a 5 % CO₂ humidified incubator. The T24 cells were cultured in Dulbecco’s modified Eagle’s medium (Gibco), supplemented with 10 % fetal bovine serum (Gibco) in a 5 % CO₂ humidified incubator at 37 °C. SV-HUC-1 cells were cultured in F12K medium.

Construction of synthetic tet-controllable shRNA targeting HOXD-AS1
HOXD-AS1 siRNA (si-HOXD-AS1) was synthesized by GenePharma, Suzhou, China according to a previous study. The sequence was GAAAGAAGGACCAAAGTAA [12]. Negative control siRNA (si-NC) was also provided from GenePharma. To construct tet-regulatable shRNAs, the company (FulenGen, Guangzhou, China) inserted the sequences of the associative tet-inducible shRNA targeting HOXD-AS1 and the negative control into tetracycline-inducible plasmid vectorspsi-LVRInU6TGP, respectively.

Cell transfection
When the cells were grown to 40 % confluence in six-well plates, they were transfected with 200 pmol si-HOXD-AS1 or si-NC using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the instructions. However, the cells were transfected with 3 μg plasmid vectors (tet-controllable HOXD-AS1 shRNA or tet-controllable NC shRNA) when they got 70 % confluence.

RNA extraction
Total RNA was obtained from the tissues or cells by using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the instructions. cDNA was transcribed from 1 μg total RNA using Reverse Transcription Kit (Takara, Dalian, China). RT-qPCR was performed on the
Clinical pathologic factors. As $P<0.009$. However, high $P=0.001$ and 25.76% in T24 ($P<0.001$). The relative expression level of LncRNA HOXD-AS1 was up-regulated in 60% (30 of 50) of bladder tumor tissues ($P<0.001$, Fig. 1a, b). Compared with the normal bladder epithelial cell line SV-HUC1, HOXD-AS1 was expressed at a higher level in bladder cell lines ($P<0.001$ in 5637, $P=0.001$ in T24, Fig. 1c, d). These results suggest that HOXD-AS1 may function as an oncogene in bladder cancer. We further analyzed the relationship between HOXD-AS1 and patients' clinical pathologic factors. As shown in Table 1, high HOXD-AS1 expression was highly correlated with tumor size, histological grade and TNM stage. The relative expression level of LncRNA HOXD-AS1 in 50 pairs of matched bladder cancer tissues was examined by performing real-time qPCR. HOXD-AS1 was significantly up-regulated in 60% (30 of 50) of bladder tumor tissues ($P<0.001$, Fig. 1a, b). Compared with the normal bladder epithelial cell line SV-HUC1, HOXD-AS1 was expressed at a higher level in bladder cell lines ($P<0.001$ in 5637, $P=0.001$ in T24, Fig. 1c, d). These results suggest that HOXD-AS1 may function as an oncogene in bladder cancer. We further analyzed the relationship between HOXD-AS1 and patients’ clinical pathologic factors. As shown in Table 1, high HOXD-AS1 expression was highly correlated with tumor size, histological grade ($P=0.044$), and TNM stage ($P=0.009$). However, high HOXD-AS1 expression was irrelevant with the parameters including gender, age and lymphatic metastasis. Taken together, these data indicated that HOXD-AS1 may act as an oncogene in the progression of bladder cancer.

Knockdown of HOXD-AS1 inhibited bladder cancer cell proliferation

5637 and T24 cells were transfected with si-HOXD-AS1 or si-NC to investigate whether HOXD-AS1 promotes proliferation of bladder cancer cells. The relative expression level of HOXD-AS1 was detected by RT-qPCR at 48 h after transfection. As shown in Fig. 2a, b, the relative level of HOXD-AS1 in bladder cancer cells was significantly decreased by si-HOXD-AS1, indicating that si-HOXD-AS1 transfection was successful ($P<0.001$ in 5637, $P=0.002$ in T24). The relative expression level of HOXD-AS1 was reduced by 68.05% in 5637 cells and 72.08% in T24 cells. Next, we performed the CCK-8 assay to explore the role of si-HOXD-AS1 in cell proliferation. As shown in Fig. 3a, b, the decreased ability of proliferation was obviously seen in 5637 and T24 cells. Furthermore, the percentage of EdU positive cells was decreased significantly after HOXD-AS1 knockdown (Fig. 4a, b). The percentage of EdU positive cells in si-HOXD-AS1 group was decreased by 20.29% in 5637 ($P=0.001$) and 25.76% in T24 ($P=0.001$). All these data suggest that high expression of HOXD-AS1 promoted the proliferation of bladder cancer cells.
Effects of HOXD-AS1 on cell migration in bladder cancer cells

As shown in Fig. 5a, compared with si-NC group, the migration capacity was significantly decreased in si-HOXD-AS1 group. As shown in Fig. 5b, the relative migration rate in the si-HOXD-AS1 group was declined by 57.83% in 5637 cells ($P < 0.001$) and 45.79% in T24 cells ($P < 0.001$). These suggest that silencing HOXD-AS1 weakened the capacity of migration in bladder cancer cells.

Knockdown of HOXD-AS1 induced apoptosis

Besides, we assume that knockdown of HOXD-AS1 may induce apoptosis. The detection of apoptosis was performed by caspase 3 ELISA assay and flow cytometry assay. As shown in Fig. 6a, b, the activities of caspase 3 in bladder cancer cells were significantly increased after transfected with si–HOXD-AS1 ($P = 0.003$ in 5637 and $P = 0.016$ in T24). What’s more, the ratio of apoptosis and early apoptosis fraction in si-HOXD-AS1 transfected cells were greater than the si-NC transfected cells (Fig. 7a–c, $P = 0.001$ in 5637 and $P < 0.001$ in T24). All these data indicate that high expression of HOXD-AS1 inhibited cell apoptosis in bladder cancer cells.

Tet-controllable HOXD-AS1 shRNA induced by dox suppressed the expression of HOXD-AS1

Cells were transiently transfected with the plasmids (3 ug) which expressed the tet-controllable HOXD-AS1 shRNA or the negative control, respectively. After transfection, different concentrations of dox (0.01 mg/ml, 0.1 mg/ml and 1 mg/ml) were added to the cells. As shown in Fig. 2c, d, the tet-controllable HOXD-AS1 shRNA inhibited the relative expression level of HOXD-AS1 in a

### Table 1: Correlation between HOXD-AS1 expression and clinical characteristics of bladder cancer patients

| Parameters | Group | Total | HOXD-AS1 expression | P value |
|------------|-------|-------|---------------------|--------|
|            |       |       | High (n = 30)       | Low (n = 20) |
| Age(years) | <60   | 31    | 17                  | 14     | 0.768 |
|            | >60   | 19    | 12                  | 7      |
| Gender     | Male  | 36    | 19                  | 17     | 0.537 |
|            | Female| 14    | 9                   | 5      |
| Tumor size (cm) | <3 cm | 18    | 6                   | 12     | 0.006 |
|            | ≥3 cm | 32    | 24                  | 8      |
| Histological grade | Low | 22    | 9                   | 13     | 0.044 |
|            | High  | 28    | 20                  | 8      |
| TNM stage | I     | 29    | 9                   | 20     | 0.009 |
|            | II/III/IV | 21    | 15                  | 6      |
| Lymphatic metastasis | N0 | 44    | 29                  | 15     | 0.650 |
|            | N1 or above | 6     | 5                   | 1      |

$P < 0.05$ was considered significant. (Chi-square test was performed)
Fig. 2 Expression changes of HOXD-AS1 after transfection of siRNA or tet-shRNA. a, b The si-HOXD-AS1 significantly reduced the expression level of HOXD-AS1 in 5637 (P < 0.001) and T24 (P = 0.002). c, d The tet-shRNA HOXD-AS1 induced by dox regulated the expression of HOXD-AS1 in a dosage-dependent manner in 5637 (P = 0.008) and T24 cells (P = 0.016).

Fig. 3 Knockdown of HOXD-AS1 by siRNA or tet-shRNA inhibits cell proliferation. CCK-8 assay was performed to investigate the cell growth curve. a, b Cell proliferation inhibition was detected in 5637 (P < 0.001) and T24 cells (P < 0.001) after transfection with si-HOXD-AS1. c, d The tet-shRNA induced by 1ug/ml dox significantly inhibits cell proliferation in 5637 (P < 0.001) and T24 cells (P < 0.001). Data were expressed as means ± SD from three independent experiments.
dose-dependent manner. When 1 mg/ml dox was added into vectors transfected 5637 and T24 cells, the expression level of HOXD-AS1 was decreased by 54.15 % in 5637 cells \((P = 0.008)\) and 55.54 % in T24 cells \((P = 0.016)\). Therefore, we chose 1 mg/ml as the best concentration for further study. These results confirmed that the tet-controllable HOXD-AS1 shRNA expressed in bladder cancer cells and inhibited the expression of HOXD-AS1.

**Tet-controllable HOXD-AS1 shRNA inhibited cell proliferation**

To investigate the role of tet-controllable HOXD-AS1 shRNA on cell proliferation in bladder cancer cells, we performed the CCK-8 and EdU assays. CCK-8 assay showed that tet-controllable HOXD-AS1 shRNA induced by dox (1 mg/ml) inhibited cell proliferation significantly compared with the negative control (Fig. 3c, d). EdU assay came up with the same results as excepted (Fig. 4d, e). The percentage of EdU positive cells was reduced by 17.62 % in 5637 cells \((P = 0.002)\) and 23.26 % in T24 cells \((P = 0.002)\) (Fig. 4f, g). These results confirmed that tet-controllable HOXD-AS1 shRNA induced by dox could significantly inhibit cell proliferation.

**Tet-controllable HOXD-AS1 shRNA inhibited cell migration**

Wound-healing assay was performed to confirm the effect of tet-controllable HOXD-AS1 shRNA on the migration ability in bladder cancer cells. As shown in Fig. 5c-f, the cells in tet-controllable HOXD-AS1 shRNA group displayed less migration ability. Compared with the negative control group, the migration rate of the tet-controllable HOXD-AS1 shRNA group was decreased by 51.2 % \((P < 0.001)\) in 5637 cells and 39.41 % \((P = 0.001)\) in T24 cells. These results indicated that tet-controllable HOXD-AS1 shRNA could strongly inhibit the migration ability of bladder cancer cells.
Finally, we investigated the possible effect of tet-controllable HOXD-AS1 shRNA on the apoptosis of bladder cancer cells. Elisa assay was performed to determine the relative activity of caspase-3. As shown in Fig. 6c, d, the relative activity of caspase-3 was increased obviously in the tet-controllable HOXD-AS1 shRNA group (P = 0.001 in 5637 and P = 0.002 in T24). Furthermore, we performed the flow cytometry assay to explore the apoptosis ratio. As shown in Fig. 7d-g, the ratio of apoptosis and early apoptosis fraction in the tet-controllable HOXD-AS1 shRNA group were increased significantly. Results suggest that the tet-controllable HOXD-AS1 shRNA could induce apoptosis in bladder cancer cells (P = 0.001 in 5637 and P < 0.001 in T24).

**Discussion**

Bladder cancer is a common malignancy, which has brought great economic burden to the world. The conventional therapy, such as surgery, radiotherapy and chemical therapy can not improve 5 year survival rate obviously [21]. Lots of literatures show that numerous
Fig. 6 Knockdown of HOXD-AS1 promotes apoptosis using ELISA assay. **a, b** Relative activities of caspase-3 in 5637 (P = 0.003) and T24 (P = 0.016) were shown after transfection with si-HOXD-AS1. **c, d** The activity of caspase-3 was increased significantly after transfection with tet-shRNA in 5637 (P = 0.001) and T24 cells (P = 0.002). Results represent the mean ± SD from three independent experiments.

Fig. 7 Transfection with si-HOXD-AS1 or tet shRNA induced apoptosis in 5637 and T24. **a-c** The rate of early apoptotic 5637 (P = 0.001) and T24 cells (P < 0.001) were increased significantly after transfection with si-HOXD-AS1. **d-g** Increased apoptotic cells were observed in tet-shRNA-transfected 5637 (P = 0.001) and T24 cells (P < 0.001). Results represent the mean ± SD from three independent experiments.
IncRNAs involve in the process of tumorigenesis and tumor progression [22–24]. What’s more, IncRNAs may serve as tumor markers and therapeutic targets, such as PVT1, Xist, ATB and MALAT1 [25–28]. HOXD-AS1 is transcribed from the HOXD gene cluster between HOXD1 and HOXD3. Besides, HOXD-AS1 is closely related to HOXD3 expression [11]. High HOXD-AS1 levels are associated with neuroblastoma progression and regulated by the PI3K/Akt pathway which has been proved to promote oncogenesis via inhibiting cell apoptosis [29]. Furthermore, a series of genes are controlled by HOXD-AS1 and these genes may serve as biomarkers of neuroblastoma recurrence and affect the patients’ survival [12]. HOXD-AS1 was also found to be overexpressed in adenocarcinomas and breast cancer, and is characterized as the indicator of poor prognosis [13, 14]. According to our knowledge, the role of HOXD-AS1 in bladder cancer is still unclear. So, it is necessary to detect the biological function of HOXD-AS1 in bladder cancer cells.

This is the first study to investigate the function of HOXD-AS1 in bladder cancer. In this research, we found that HOXD-AS1 was up-regulated in bladder cancer tissues and cells, indicating that HOXD-AS1 may act as an oncogene. Further experiments demonstrate that HOXD-AS1 may be viewed as a promising tumor maker. High expression of HOXD-AS1 was positively associated with clinicopathologic features, including tumor size, histological grade and TMN stage. To get a better insight to the function of HOXD-AS1, we silenced HOXD-AS1 with specific siRNA and found that inhibition of HOXD-AS1 could inhibit cell proliferation, suppress cell migration and increase apoptosis in bladder cancer cells. Significantly, it is the first research to verify the oncogenic role of HOXD-AS1 in bladder cancer. Further studies on the modulation of HOXD-AS1 expression and more thorough molecular mechanisms are needed.

With the rapid development of synthetic biology, more synthetic gene networks are applied in medical research, including immuno-regulatory networks and cancer therapy gene circuits [30–32]. Synthetic biological gene switches including ABA transcriptional switches, tet-on post-transcriptional switches and hoechst aptamer translational switches form the basis to engineer novel and complex gene networks [33–35]. Synthetic tet-on switch is commonly accepted and is employed to control genes expression [36, 37]. Inspired by these previous works, we constructed the synthetic tetracycline-controllable shRNA targeting HOXD-AS1 and detected its anti-cancer effects in bladder cancer cells. Our data demonstrated that the synthetic tetracycline-controllable shRNA targeting HOXD-AS1 effectively suppressed the expression level of HOXD-AS1 in a dose-dependent manner, which subsequently inhibited the ability of proliferation/migration and induced apoptosis in bladder cancer cells. We suppose that the synthetic tetracycline-controllable shRNA could control multiple genes expression at the same time and increasing the transfection efficiency could improve the efficiency of this device.

It should be noted that there seems to be no significant decrease in proliferation between 48 and 72 h in both T24 and 5637 cells. But the apoptosis assay shows that there is a significant increase at 48 h. One possible explanation for these contradictory results is that the change in proliferation rate may not be readily reflected by the rate of increase of OD value when the cell number was continuously increased.

Conclusions

In conclusion, our research suggested that HOXD-AS1 may get involved in the bladder cancer carcinogenesis by activating endogenous cancer-related molecular pathways. Therefore, HOXD-AS1 may become a potential and promising therapeutic target. Furthermore, we use the synthetic biology component to construct the synthetic tetracycline-controllable shRNA for controlling the expression of HOXD-AS1 artificially and inhibiting the progression of bladder cancer cells. Maybe, it can provide a novel approach for effectively suppressing specific oncogenes and promote the development of new anticancer method in the area of medical synthetic biology. This work may bring a promising future to fight against bladder cancer.

Acknowledgments

The authors are appreciative to the donors, whose names were not included in the author list, but who participated in this program. This work was funded by the National Key Basic Research Program of China (973 Program) (2014CB745201), the Chinese High-Tech (863) Program (2014AA020607), National Natural Science Foundation of China (81402103), International Science & Technology Cooperation program of China (ISTCP) (2014DFA31050), the National Science Foundation Projects of Guangdong Province (2014A030313717), the Shenzhen Municipal Government of China (ZDSYS201504301722174, JCYJ20150330102720130, GJHZ20150316154912494), and Special Support Funds of Shenzhen for Introduced High-Level Medical Team.

Authors’ contributions

JL, CZ, YL and MC performed the experiments. ZC and AH analysed the data. JL, YC, YZ and LL wrote the primary manuscript. JL, CZ, YL and MC designed the experiments and modified the paper. YC, ZC and AH created the tables and figures. HW supervised the project. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Key Laboratory of Medical Reprogramming Technology, Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen 518036, People’s Republic of China. 2 Anhui Medical University, Heifei 230000, Anhui Province, People’s Republic of China. 3 Shantou University Medical College, Shantou 515041, Guangdong Province, People’s Republic of China. 4 Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen 518036, People’s Republic of China.
People’s Republic of China. 2Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai 200000, People’s Republic of China. 3Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, People’s Republic of China.

Received: 29 April 2016 Accepted: 8 June 2016 Published online: 21 June 2016

References

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, et al. Cancer treatment and survivorship statistics. 2014. CA Cancer J Clin. 2014;64(4):252–71.
2. Nieder AM, Mackinnon JA, Huang Y, Fleming LE, Koniaris LG, et al. Florida bladder cancer trends 1981 to 2004: minimal progress in decreasing advanced disease. J Urol. 2008;179(2):491–5.
3. Chen J, Wang L, Tang Y, Gong G, Liu L, et al. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with progression of muscle-invasive bladder cancer. J Exp Clin Cancer Res. 2016;35:2.
4. Brausi MA. Primary prevention and early detection of bladder cancer: two main goals for urologists. Eur Urol. 2013;63(2):242–3.
5. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186(2):2158–67.
6. Stein JP, Limkikayak V, Cote R, Groshen S, Feng AC, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.
7. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003;21(2):690–6.
8. Mallardo M, Poltronieri P, DeRin G. Non-protein coding RNA and differential expression in cancers: a review. J Exp Clin Cancer Res. 2008;27:19.
9. Bimey E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799–816.
10. Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015;21(11):1283–61.
11. Batagov AO, Yarmishyn AA, Jenjaroenpun P, Tan JZ, Nishida Y, et al. Role of genomic architecture in the expression dynamics of long noncoding RNAs during differentiation of human neuroblastoma cells. BMC Syst Biol. 2013;7(51).
12. Yarmishyn AA, Batagov AO, Tan JZ, Sundaram GM, Sampath P, et al. HOXD-AS1 is a novel IncRNA encoded in HOXD cluster and a marker underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24(11):1679–88.
13. Champine PJ, Michaelson J, Welch DR, DeWald DB. Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clin Exp Metastasis. 2007;24(7):551–65.
14. Shiraiishi M, Sekiguchi A, Oates AJ, Terry MJ, Miyamoto Y. HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. Oncogene. 2002;21(22):3659–62.
15. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010;10(5):361–71.
16. Lienert F, Lohmueller JJ, Garg A, Silver PA. Synthetic biology in mammalian cells: next generation research tools and therapeutics. Nat Rev Mol Cell Biol. 2014;15(2):95–107.
17. Khall A5, Khall AS, Collins JJ. Chromatin regulation at the frontier of synthetic biology. Nat Rev Genet. 2015;16(3):159–71.
18. Khall AS, Collins JJ. Synthetic biology: applications come of age. Nat Rev Genet. 2010;11(5):367–79.
19. Rosser CJ, Urdiñol V, Goodson S. Urinary biomarkers of bladder cancer: an update and future perspectives. Biomark Med. 2013;7(5):779–90.